REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

The Healer

Recoverybeginner
12
Share
Peptides

2

Avg Daily mcg

0

Level

beginner

Added

May 7, 2026

Overview

The Healer is a foundational recovery stack built on the two most well-researched tissue repair peptides in the field. Designed for beginners entering the world of peptide therapy, this straightforward two-peptide protocol delivers powerful regenerative signaling without the complexity of advanced multi-compound stacks. It represents the essential starting point for anyone seeking accelerated recovery from injuries, chronic pain conditions, or general tissue wear. BPC-157, administered at 250mcg subcutaneously once daily, is a body protection compound originally isolated from human gastric juice. This 15-amino-acid peptide has accumulated an impressive body of preclinical research demonstrating its ability to heal virtually every tissue type studied, including muscle, tendon, ligament, bone, intestinal lining, and neural tissue. It works through multiple pathways: promoting angiogenesis via VEGF upregulation, accelerating fibroblast migration to injury sites, modulating nitric oxide systems for improved blood flow, and protecting cells from oxidative damage. Daily subcutaneous administration near an injury site provides consistent local tissue concentrations for optimal repair signaling. TB-500, dosed at 2.5mg subcutaneously twice weekly, is a synthetic version of the active region of Thymosin Beta-4, a naturally occurring 43-amino-acid protein involved in tissue repair throughout the body. TB-500 promotes healing by upregulating actin polymerization, which enhances cell migration and proliferation at injury sites. Unlike BPC-157, TB-500 distributes systemically regardless of injection location, making it effective for diffuse or hard-to-reach injuries. It also exhibits significant anti-inflammatory properties and has been shown to reduce scar tissue formation, promoting more functional tissue restoration. The synergy between these two peptides is well-established in the peptide therapy community. BPC-157 provides targeted local repair amplification while TB-500 creates a systemic pro-healing environment. Together they address injuries from multiple angles: inflammation reduction, blood vessel formation, cell migration, and structural protein synthesis. This stack is ideal for athletes recovering from training injuries, individuals with chronic musculoskeletal pain, or anyone experiencing slow healing. The protocol runs for 4-8 weeks depending on injury severity. No complex cycling is required, making it the perfect entry point for peptide therapy newcomers. Subcutaneous injection technique is simple to learn and well-tolerated.

Dosing Protocol

BPC-157

Every day· subcutaneous

Read more about BPC-157 →

250mcg

per dose

TB-500

Twice per week· subcutaneous

Read more about TB-500 →

2.5mg

per dose

Goals & Evidence

Evidence tier:community

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.